810
Participants
Start Date
April 15, 2016
Primary Completion Date
December 19, 2016
Study Completion Date
December 19, 2016
Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
0.5 milliliter (mL), Intramuscular
Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
0.5 mL, Intramuscular
Investigational Site Number 006, Rochester
Investigational Site Number 007, Hermitage
Investigational Site Number 009, Erie
Investigational Site Number 016, Birmingham
Investigational Site Number 032, Dothan
Investigational Site Number 024, Tullahoma
Investigational Site Number 013, Bardstown
Investigational Site Number 027, Nicholasville
Investigational Site Number 011, Fairfield
Investigational Site Number 019, Cincinnati
Investigational Site Number 025, Huber Heights
Investigational Site Number 021, Kettering
Investigational Site Number 010, Troy
Investigational Site Number 012, Fargo
Investigational Site Number 028, St Louis
Investigational Site Number 008, Kansas City
Investigational Site Number 031, Omaha
Investigational Site Number 023, Lincoln
Investigational Site Number 015, Metairie
Investigational Site Number 022, Jonesboro
Investigational Site Number 017, South Jordan
Investigational Site Number 020, Salt Lake City
Investigational Site Number 003, Salt Lake City
Investigational Site Number 026, Mesa
Investigational Site Number 005, Downey
Investigational Site Number 014, La Puente
Investigational Site Number 029, San Diego
Investigational Site Number 001, San Diego
Investigational Site Number 018, Woburn
Investigational Site Number 030, San Juan
Sanofi Pasteur, a Sanofi Company
INDUSTRY